I. Amendments to the Claims

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising a compound of Formula I,



(I)

wherein

R^1 is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidazol-2-yl;



wherein R^4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; $NHCH_2CH_2OX$ wherein X represents an in vivo hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxycarbonyl; and

R^2 and R^3 are independently selected from H, NO_2, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S-, loweralkyl, and Z(O)OR^7 wherein Z is selected from C and S and R^7 is selected from H, loweralkylamino and arylamino, with the provisos that: (i) R^2 and R^3 are not both hydrogen, and (ii) when R^3 is NO_2, R^1 is not benzyl;

~~and~~ or a pharmaceutically acceptable ~~salts~~ salt thereof~~, in an amount effective to inhibit neurotrophin-mediated activity,~~ and

a pharmaceutically acceptable carrier.

2. (Currently amended) ~~A pharmaceutical composition~~ The method according to claim 1, wherein R^1 is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidazol-2-yl;



wherein R^4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; $NHCH_2CH_2OX$ wherein X represents an in vivo hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, NO_2, halo, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that R^2 and R^3 are not both hydrogen.

3. (Currently amended) ~~A pharmaceutical composition~~ The method according to claim 2, wherein R^1 is selected from aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with hydroxyloweralkyl; benzimidazol-2-yl; $NHCH_2CH_2OX$ wherein X represents an in vivo hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, NO_2, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that R^2 and R^3 are not both hydrogen.

4. (Currently amended) ~~A pharmaceutical composition~~ The method according to claim 3, wherein R^1 is selected from amino monosubstituted or disubstituted with hydroxyloweralkyl;

$NHCH_2CH_2OX$ wherein X represents an in vivo hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, loweralkyl and NO_2, with the proviso that R^2 and R^3 are not both hydrogen.

5. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

2-{2-(4-Methylphenylsulphonamido)phenyl}-6-(N,N-dimethylamino)-naphthalimide;

N-Octyl-5-nitronaphthalimide;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

2-(Benzimidazol-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

3-Methyl-3-(1,3-dioxo-5-nitro(1H,3H)benz[de]isoquinolyl)butyric acid methylester;

N-(4-Ethoxyphenyl)-5-nitronaphthalimide;

Naphthalic acid-N,N'-diimide;

5-Amino-N-butylnaphthalimide; and

N-(1,3-Dioxo-6-phenylmercapto-1,2,3,4-tetrahydrobenzo[i]isoquinoline)-aminoethanol; ~~and~~ or

a pharmaceutically acceptable ~~salts~~ salt thereof~~, in an amount effective to inhibit~~

~~neurotrophin-mediated activity~~; and

a pharmaceutically acceptable carrier.

6. (Currently amended) ~~A pharmaceutical composition~~ The method according to claim 5 wherein the compound is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

N-Octyl-5-nitronaphthalimide;

3-Amino-7,4-bis(ethyl-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline); and

2-(Benzimidazol-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline.

7. (Currently amended) ~~A pharmaceutical composition~~ The method according to claim 1 wherein the compound of Formula I is N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt.

8. (Cancelled)

9. (Cancelled)

10. (Currently amended) ~~A~~ The method ~~for inhibiting a neurotrophin-mediated activity comprising the~~ according to claim 1, wherein said step of administering comprises the step of exposing neuron cells to an effective amount of a the pharmaceutical composition ~~as defined in claim 1~~.

11. (Cancelled)

12. (Currently amended) ~~A~~ The method as defined in claim ~~11~~ 1, wherein said composition is administered intraventricularly.

13. (Currently amended) ~~An~~ A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising an *in vivo* hydrolyzable ester or amide of a compound selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

2-(2-Hydroxyphenyl)naphthalimide; and

a pharmaceutically acceptable carrier.

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Currently amended) A method of inhibiting a neurotrophin-mediated activity in a mammal comprising the step of administering to said mammal an effective amount of a pharmaceutical composition comprising N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt, ~~in an amount effective to inhibit pain,~~ and a pharmaceutically acceptable carrier.

21. (Cancelled).

22. (Currently amended) ~~A~~ The method ~~for treating pain comprising the~~ according to claim 20, wherein said step of administering comprises the step of exposing neuron cells to an effective amount of ~~a~~ the pharmaceutical composition ~~as defined in claim 20~~.

23. (Cancelled)

24. (Currently amended) ~~A~~ The method as defined in claim ~~23~~20, wherein said composition is administered intraventricularly.

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (New) The method as defined in claim 1, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a $p75^{NGFR}$ receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.

36. (New) The method as defined in claim 5, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a $p75^{NGFR}$ receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.

37. (New) The method as defined in claim 13, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a $p75^{NGFR}$ receptor,

neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.

38. (New) The method as defined in claim 20, wherein the neurotrophin-mediated activity is selected from the group consisting of neurotrophin binding to a $p75^{NGFR}$ receptor, neurotrophin binding to a trk receptor, neuron process formation, neurite outgrowth and enzyme induction.